Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes.
The next generation of anxiolytics may be subtype-selective partial agonists at GABA-A receptors. By exploiting new psychopharmacologic principles, such as the targeting of receptor subtypes that have unique subunits and the partial activation of these subtypes with stabilizers, we may eventually have anxiolytics that are rapid acting, but without sedation, amnesia, or dependence.